Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

32,500

Employees32,500

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

32,500

Employees32,500

BMY Key Statistics

Market cap

128.44B

Market cap128.44B

Price-Earnings ratio

14.07

Price-Earnings ratio14.07

Dividend yield

3.93%

Dividend yield3.93%

Average volume

14.60M

Average volume14.60M

High today

$64.02

High today$64.02

Low today

$61.95

Low today$61.95

Open price

$63.54

Open price$63.54

Volume

15.84M

Volume15.84M

52 Week high

$68.64

52 Week high$68.64

52 Week low

$42.52

52 Week low$42.52

Stock Snapshot

Bristol-Myers Squibb(BMY) stock is priced at $63.00, giving the company a market capitalization of 128.44B. It carries a P/E multiple of 14.07 and pays a dividend yield of 3.93%.

On 2026-09-29, Bristol-Myers Squibb(BMY) stock moved within a range of $61.95 to $64.02. With shares now at $63.00, the stock is trading +1.7% above its intraday low and -1.6% below the session's peak.

Trading volume for Bristol-Myers Squibb(BMY) stock has reached 15.84M, versus its average volume of 14.6M.

The stock's 52-week range extends from a low of $42.52 to a high of $68.64.

BMY News

Simply Wall St 12h

Why Is Bristol-Myers Squibb In Focus After New Phase 3 Myeloma Data?

Bristol-Myers Squibb (NYSE:BMY) reported the first Phase 3 EXCALIBER-RRMM results for ZENBEXUS in relapsed or refractory multiple myeloma. The pivotal trial sh...

MarketWatch 4d

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch

...

Simply Wall St 4d

What Bristol Myers Squibb Stock’s Strong Buy Upgrade Means For Shareholders

In recent weeks, Bristol-Myers Squibb reported two-year Phase 3 POETYK PsA-2 data for Sotyktu in psoriatic arthritis, expanded access to ZENBEXUS through a rest...

Analyst ratings

58%

of 31 ratings

Buy

35.5%

Hold

58.1%

Sell

6.5%

More BMY News

TipRanks 5d

Bristol-Myers Squibb: Pipeline Uncertainties and Limited IPF Upside Lead Flynn to Reiterate Sell Rating and Maintain $40 Price Target

Bristol-Myers Squibb, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn from Morgan Stanley maintained a Sell r...

TipRanks 5d

BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) has completed a Phase 1 study in China f...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.